Asterand has extended its collaboration with Bristol-Myers Squibb for as many as three years, for access to Asterand’s PhaseZERO drug discovery services and XpressBANK of human tissue and clinical samples for validation of early drug targets and support for compound optimization. Asterand chief executive officer, Martyn Coombs, commented: “This decision by BMS is an important validation of Asterand’s products and services. Asterand provides human based solutions that improve decis...